f technical hurdles "might take 10 years," =amm figures. That seems somewhat optimistic if you consider Glaxo's =nvestment so far in bioelectronics. Melinda Stubbee, the company's director of =ommunications, says it has spent roughly $60 million in the area, a pittance compared =ith its $6.5 billion in total R.